期刊文献+

3D腹腔镜在腹腔镜辅助胃癌根治术中的应用价值 被引量:15

Application Value of Three Dimensional Laparoscopic-assisted Radical Gastrectomy
下载PDF
导出
摘要 目的探讨3D腹腔镜在辅助性D2胃癌根治术的应用价值。方法采用前瞻性研究对2014年1月~2015年7月27例3D腹腔镜辅助胃癌根治术(3D组)与24例2D腹腔镜辅助胃癌根治术(2D组)的疗效进行比较。结果 3D组手术时间(183. 6±39. 5) min,与2D组(197. 8±36. 2) min差异无显著性(t=1. 332,P=0. 189);淋巴结清扫数目(32. 6±5. 3)枚,与2D组(29. 9±4. 3)枚差异无显著性(t=1. 982,P=0. 053);术中出血量(65. 9±28. 7) ml,显著少于2D组(88. 3±29. 2) ml(t=2. 759,P=0. 008);术后排气时间(72. 3±8. 3) h,与2D组(75. 3±9. 2) h差异无显著性(t=1. 224,P=0. 227);术后住院时间(8. 7±2. 2) d,与2D组(9. 3±2. 7) d无显著性差异(t=0. 874,P=0. 386);术后并发症发生率7. 4%(2/27),与2D组12. 5%(3/24)无显著性差异(χ~2=0. 019,P=0. 890);术后3 d平均腹腔引流量(47. 5±18. 3) ml,明显少于2D组(67. 3±23. 1) ml(t=3. 411,P=0. 001)。2组术后2年无瘤生存率无统计学差异(log-rank χ~2=0. 780,P=0. 377)。结论 3D腹腔镜D2胃癌根治术中出血量和术后腹腔引流量明显少于2D,两者疗效相当。 Objective To analyze clinical value of three dimensional laparoscopic-assisted radical D2 gastrectomy.Methods From January 2014 to July 2015,we performed 27 cases of radical D2 laparoscopic-assisted gastrectomy by employing Einstein Vision 3D laparoscopic system(3D group),as compared to 24 cases of two dimensional laparoscopic radical gastrectomy(2D group)to evaluate application value.Results The surgery time of the 3D group(183.6±39.5)min was slightly shorter than the 2D group[(197.8±36.2)min,t=1.332,P=0.189].There was no significant difference in average number of lymph node dissection between the 3D group(32.6±5.3)and the 2D group(29.9±4.3,t=1.982,P=0.053).The amount of bleeding in the 3D group(65.9±28.7 ml)was significantly lower than the 2D group(88.3±29.2 ml,t=2.759,P=0.008).There was no significant difference for postoperative complications incidence between the 3D group(7.4%)and the 2D group(12.5%,χ^2=0.019,P=0.890).There was no significant difference for postoperative exhaust time(72.3±8.3 h vs.75.3±9.2 h,t=1.224,P=0.227)and postoperative hospital stay(8.7±2.2 d vs.9.3±2.7 d,t=0.874,P=0.386)between the 3D group and 2D group.The postoperative volume of drainage in 3 days of the 3D group(47.5±18.3 ml)was significant less than the 2D group(67.3±23.1 ml,t=3.411,P=0.001).There was no significant difference in 2-year disease-free survival rate between the two groups(χ^2=0.780,P=0.377).Conclusion The 3D laparoscopic assisted D2 radical gastrectomy has less intraoperative blood loss and postoperative intraperitoneal drainage volume than 2D laparoscopic D2 radical gastrectomy,while both have equal effects.
作者 李家新 缪刚刚 毛须平 Li Jiaxin;Miao Ganggang;Mao Xuping(Department of Gastrointestinal Surgery,Danyang Hospital Affiliated to Nantong University,Danyang 212300,China)
出处 《中国微创外科杂志》 CSCD 北大核心 2018年第12期1099-1102,共4页 Chinese Journal of Minimally Invasive Surgery
关键词 3D腹腔镜 2D腹腔镜 胃癌 根治性胃切除术 3D laparoscopy 2D laparoscopy Gastric cancer Radical gastrectomy
  • 相关文献

参考文献7

二级参考文献74

  • 1李双,吴晓江,张连海,宗祥龙,陕飞,季加孚,李子禹.腹腔镜辅助胃癌根治手术学习曲线的初步探讨[J].消化肿瘤杂志(电子版),2011,3(3):156-159. 被引量:17
  • 2Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a mul- ticenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group[J]. Ann Surg,1999,230(2):170-178.
  • 3Lee SL, Lee HH, Ko YH, et al. Relevance of hepatoduodenal lig- ament lymph nodes in resectional surgery for gastric cancer [J]. Br J Surg,2014,101 (5):518-522.
  • 4Kluijt I, Sijmons RH, Hoogerbrugge N, et al.Famihal gastric can- cer: guidelines for diagnosis, treatment and periodic surveillance [J]. Fam Cancer,2012,11(3):363-369.
  • 5Anaya DA, Chang GJ, Rodriguez-Bigas MA. Extracolonic mani- festations of hereditary colorectal cancer syndromes [ J ]. Clin Co- lon Rectal Surg,2008,21 (4):263-272.
  • 6Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant condi- tions of the upper GI tract [J]. Gastrointest Endosc,2006,63(4): 570-580.
  • 7Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, muhicenter, phase m study of fluorouraeil, leueovorin, and iri- notecan versus epirubicin, eisplatin, and capeeitabine in ad- vanced gastric adenoeareinoma: a French intergroup (Federation Franeophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidiseiplinaire en Oncologie) study[J]. J Clin Oncol,2014,32 (31):3520-3526.
  • 8Spratlln JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoelonal antibody targeting the vascular endothelial growth factor receptor-2 [J]. J Clin Oncol,2010,28 (5):780-787.
  • 9Wilke H, Muro K, Van Cutsem E, et al. Ramueirumab plus pacl- itaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adeno- carcinoma (RAINBOW): a double-blind, randomised phase 3 trial [ J ]. Lane et Oncol,2014,15 ( 11 ): 1224-1235.
  • 10Ford HE, Marshall A, Bridgewater JA, et al. Doeetaxel versus ac- tive symptom control for refractory oesophagogastric adenoearei- noma (COUGAR-02): an open-label, phase 3 randomised con- trolled trial[J]. Lancet Onc01,2014,15(1):78-86.

共引文献98

同被引文献181

引证文献15

二级引证文献115

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部